1. What Happened?: Bukwang Pharm’s H1 2025 Performance
Bukwang Pharm recorded consolidated revenue of KRW 90.4 billion (up 27% YoY) and operating profit of KRW 5 billion (turnaround) in the first half of 2025. The successful launch of ‘Latuda’ and steady sales of existing products drove this growth.
2. Why?: Drivers of the Turnaround and Growth
- Successful market entry of ‘Latuda’
- Stable sales of existing products like Dexid and Ferova
- Improved R&D efficiency
- Strengthened financial structure through capital increase
3. So What?: Implications for Investors
This semi-annual report demonstrates Bukwang Pharm’s positive fundamental improvements and future growth potential. The continued growth of ‘Latuda’ and the clinical progress of the CNS therapeutics pipeline are particularly noteworthy.
4. Investor Action Plan
- Monitor ‘Latuda’ Sales Trends: Keep track of market share and sales volume changes.
- Follow R&D Pipeline Progress: Closely monitor clinical trial results and future development plans.
- Prepare for Exchange Rate and Interest Rate Volatility: Analyze the company’s strategies to address external environmental changes.
- Analyze the Competitive Landscape: Understand competitor trends and market changes to inform investment decisions.
- Review the Use of Funds from the Capital Increase: Monitor the efficiency and effectiveness of fund allocation.